Type II Inhibitors Targeting CDK2

ACS Chemical Biology

Volumn 10, Issue 9, 2015, Pages 2116-2125

  Alexander, Leila T ^a,b,f   Möbitz, Henrik ^c   Drueckes, Peter ^c   Savitsky, Pavel ^a   Fedorov, Oleg ^a,d   Elkins, Jonathan M ^a,d   Deane, Charlotte M ^b   Cowan Jacob, Sandra W ^c   Knapp, Stefan ^a,d,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e GOETHE UNIVERSITY   (Germany)

^f ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOPYRIDINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLINE; K 03859; K 03861; MAGNESIUM ION; UNCLASSIFIED DRUG; CDK2 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; BINDING KINETICS; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG TARGETING; ENERGY TRANSFER; ENZYME CONFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; SITE DIRECTED MUTAGENESIS; WILD TYPE; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOLECULAR MODEL; PROTEIN CONFORMATION; PROTEIN DOMAIN;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; BINDING SITES; CYCLIN-DEPENDENT KINASE 2; CYCLINS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS;

EID: 84941931457     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00398     Document Type: Article

References (44)

1. Liu, Y. and Gray, N. (2006) Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2, 358-364 10.1038/nchembio799
2. Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., and Gray, N. (2014) Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? ACS Chem. Biol. 9, 1230-1241 10.1021/cb500129t
3. Chaikuad, A., Tacconi, E., Zimmer, J., Liang, Y., Gray, N., Tarsounas, M., and Knapp, S. (2014) A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics Nat. Chem. Biol. 10, 853-860 10.1038/nchembio.1629
4. Noble, M., Endicott, J., and Johnson, L. (2004) Protein Kinase Inhibitors: Insights into Drug Design from Structure Science 303, 1800-1805 10.1126/science.1095920
5. Hubbard, S. R., Wei, L., Ellis, L., and Hendrickson, W. A. (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor Nature 372, 746-754 10.1038/372746a0
6. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289, 1938-1942 10.1126/science.289.5486.1938
7. Kufareva, I. and Abagyan, R. (2008) Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states J. Med. Chem. 51, 7921-7932 10.1021/jm8010299
8. Hasegawa, M., Nishigaki, N., Washio, Y., Kano, K., Harris, P., Sato, H., Mori, I., West, R., Shibahara, M., Toyoda, H., Wang, L., Nolte, R., Veal, J., and Cheung, M. (2007) Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors J. Med. Chem. 50, 4453-4470 10.1021/jm0611051
9. Hodous, B., Geuns-Meyer, S., Hughes, P., Albrecht, B., Bellon, S., Caenepeel, S., Cee, V., Chaffee, S., Emery, M., Fretland, J., Gallant, P., Gu, Y., Johnson, R., Kim, J., Long, A., Morrison, M., Olivieri, P., Patel, V., Polverino, A., Rose, P., Wang, L., and Zhao, H. (2007) Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors Bioorg. Med. Chem. Lett. 17, 2886-2889 10.1016/j.bmcl.2007.02.067
10. Zuccotto, F., Ardini, E., Casale, E., and Angiolini, M. (2010) Through the gatekeeper door: exploiting the active kinase conformation J. Med. Chem. 53, 2681-2694 10.1021/jm901443h
11. Garske, A. L., Peters, U., Cortesi, A. T., Perez, J. L., and Shokat, K. M. (2011) Chemical genetic strategy for targeting protein kinases based on covalent complementarity Proc. Natl. Acad. Sci. U. S. A. 108, 15046-15052 10.1073/pnas.1111239108
12. Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P., Pierotti, M., and Pilotti, S. (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127, 294-299 10.1053/j.gastro.2004.02.021
13. Kobayashi, S., Boggon, T., Dayaram, T., Jänne, P., Kocher, O., Meyerson, M., Johnson, B., Eck, M., Tenen, D., and Halmos, B. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 352, 786-792 10.1056/NEJMoa044238
14. Azam, M., Seeliger, M., Gray, N., Kuriyan, J., and Daley, G. (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine Nat. Struct. Mol. Biol. 15, 1109-1118 10.1038/nsmb.1486
15. Quintas-Cardama, A., Tong, W., Manshouri, T., Vega, F., Lennon, P. A., Cools, J., Gilliland, D. G., Lee, F., Cortes, J., Kantarjian, H., and Garcia-Manero, G. (2008) Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies Leukemia 22, 1117-1124 10.1038/leu.2008.80
16. Emrick, M., Lee, T., Starkey, P., Mumby, M., Resing, K., and Ahn, N. (2006) The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity Proc. Natl. Acad. Sci. U. S. A. 103, 18101-18106 10.1073/pnas.0608849103
17. Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., and Saxena, K. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Mol. Cell 13, 169-178 10.1016/S1097-2765(03)00505-7
18. Wang, Z., Harkins, P. C., Ulevitch, R. J., Han, J., Cobb, M. H., and Goldsmith, E. J. (1997) The structure of mitogen-activated protein kinase p38 at 2.1-A resolution Proc. Natl. Acad. Sci. U. S. A. 94, 2327-2332 10.1073/pnas.94.6.2327
19. Shan, Y., Seeliger, M., Eastwood, M., Frank, F., Xu, H., Jensen, M. O., Dror, R., Kuriyan, J., and Shaw, D. (2009) A conserved protonation-dependent switch controls drug binding in the Abl kinase Proc. Natl. Acad. Sci. U. S. A. 106, 139-144 10.1073/pnas.0811223106
20. Martin, M., Zhu, J.-Y., Lawrence, H., Pireddu, R., Luo, Y., Alam, R., Ozcan, S., Sebti, S., Lawrence, N., and Schönbrunn, E. (2012) A Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora A ACS Chem. Biol. 7, 698-706 10.1021/cb200508b
21. Hari, S., Merritt, E., and Maly, D. (2013) Sequence determinants of a specific inactive protein kinase conformation Chem. Biol. 20, 806-815 10.1016/j.chembiol.2013.05.005
22. Atwell, S., Adams, J., Badger, J., Buchanan, M., Feil, I., Froning, K., Gao, X., Hendle, J., Keegan, K., Leon, B., Müller-Dieckmann, H., Nienaber, V., Noland, B., Post, K., Rajashankar, K. R., Ramos, A., Russell, M., Burley, S., and Buchanan, S. (2004) A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase J. Biol. Chem. 279, 55827-55832 10.1074/jbc.M409792200
23. Johnson, L. (2009) Protein kinase inhibitors: contributions from structure to clinical compounds Q. Rev. Biophys. 42, 1-40 10.1017/S0033583508004745
24. Möbitz, H. (2015) The ABC of protein kinase conformations Biochim. Biophys. Acta, Proteins Proteomics 10.1016/j.bbapap.2015.03.009
25. Salonen, L., Ellermann, M., and Diederich, F. (2011) Aromatic Rings in Chemical and Biological Recognition: Energetics and Structures Angew. Chem., Int. Ed. 50, 4808-4842 10.1002/anie.201007560
26. Chakrabarti, P. and Bhattacharyya, R. (2007) Geometry of nonbonded interactions involving planar groups in proteins Prog. Biophys. Mol. Biol. 95, 83-137 10.1016/j.pbiomolbio.2007.03.016
27. Kornev, A. and Taylor, S. (2010) Defining the conserved internal architecture of a protein kinase Biochim. Biophys. Acta, Proteins Proteomics 1804, 440-444 10.1016/j.bbapap.2009.10.017
28. Wood, E., Truesdale, A., McDonald, O., Yuan, D., Hassell, A., Dickerson, S., Ellis, B., Pennisi, C., Horne, E., Lackey, K., Alligood, K., Rusnak, D., Gilmer, T., and Shewchuk, L. (2004) A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) Cancer Res. 64, 6652-6659 10.1158/0008-5472.CAN-04-1168
29. Eswaran, J., Bernad, A., Ligos, J., Guinea, B., Debreczeni, J., Sobott, F., Parker, S., Najmanovich, R., Turk, B., and Knapp, S. (2008) Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture Structure 16, 115-124 10.1016/j.str.2007.10.026
30. Reikofski, J. and Tao, B. Y. (1992) Polymerase chain reaction (PCR) techniques for site-directed mutagenesis Biotechnol. Adv. 10, 535-547 10.1016/0734-9750(92)91451-J
31. Heckman, K. and Pease, L. (2007) Gene splicing and mutagenesis by PCR-driven overlap extension Nat. Protoc. 2, 924-932 10.1038/nprot.2007.132
32. Savitsky, P., Bray, J., Cooper, C., Marsden, B., Mahajan, P., Burgess-Brown, N., and Gileadi, O. (2010) High-throughput production of human proteins for crystallization: the SGC experience J. Struct. Biol. 172, 3-13 10.1016/j.jsb.2010.06.008
33. Keates, T., Cooper, C., Savitsky, P., Allerston, C., Phillips, C., Hammarström, M., Daga, N., Berridge, G., Mahajan, P., Burgess-Brown, N., Müller, S., Gräslund, S., and Gileadi, O. (2012) Expressing the human proteome for affinity proteomics: optimizing expression of soluble protein domains and in vivo biotinylation New Biotechnol. 29, 515-525 10.1016/j.nbt.2011.10.007
34. Rosenblatt, J., De Bondt, H., Jancarik, J., Morgan, D., and Kim, S.-H. (1993) Purification and Crystallization of Human Cyclin-dependent Kinase 2 J. Mol. Biol. 230, 1317-1319 10.1006/jmbi.1993.1248
35. De Bondt, H., Rosenblatt, J., Jancarik, J., Jones, H., Morgant, D., and Kim, S.-H. (1993) Crystal structure of cyclin-dependent kinase 2 Nature 363, 595-602 10.1038/363595a0
36. Fedorov, O., Niesen, F., and Knapp, S. (2012) Kinase inhibitor selectivity profiling using differential scanning fluorimetry Methods Mol. Biol. 795, 109-118 10.1007/978-1-61779-337-0
37. Perrin, D., Frémaux, C., and Shutes, A. (2010) Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery Expert Opin. Drug Discovery 5, 51-63 10.1517/17460440903493431
38. Winn, M., Ballard, C., Cowtan, K., Dodson, E., Emsley, P., Evans, P., Keegan, R., Krissinel, E., Leslie, A., McCoy, A., McNicholas, S., Murshudov, G., Pannu, N., Potterton, E., Powell, H., Read, R., Vagin, A., and Wilson, K. (2011) Overview of the CCP4 suite and current developments Acta Crystallogr., Sect. D: Biol. Crystallogr. 67, 235-242 10.1107/S0907444910045749
39. Battye, G., Kontogiannis, L., Johnson, O., Powell, H., and Leslie, A. (2011) iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM Acta Crystallogr., Sect. D: Biol. Crystallogr. 67, 271-281 10.1107/S0907444910048675
40. Evans, P. (2006) Scaling and assessment of data quality Acta Crystallogr., Sect. D: Biol. Crystallogr. 62, 72-82 10.1107/S0907444905036693
41. McCoy, A., Grosse-Kunstleve, R., Adams, P., Winn, M., Storoni, L., and Read, R. (2007) Phaser crystallographic software J. Appl. Crystallogr. 40, 658-674 10.1107/S0021889807021206
42. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 486-501 10.1107/S0907444910007493
43. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 53, 240-255 10.1107/S0907444996012255
44. Davis, I., Leaver-Fay, A., Chen, V., Block, J., Kapral, G., Wang, X., Murray, L., Arendall, B., Snoeyink, J., Richardson, J., and Richardson, D. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids Nucleic Acids Res. 35, W375-W383 10.1093/nar/gkm216